We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
HEM Pharma is a biopharmaceutical company specializing in microbiome-based new drug development. Its primary development areas include treatments for neurological diseases (such as Alzheimer's and Parkinson's disease), metabolic diseases, and inflammatory bowel diseases. The company researches and develops new drugs by leveraging its proprietary HEM-Platform technology.
HEM파마는 마이크로바이옴 기반 신약 개발에 주력하는 바이오 제약 기업입니다. 신경계 질환(알츠하이머, 파킨슨병 등), 대사성 질환, 염증성 장 질환 치료제를 주요 개발 분야로 삼고 있으며, 독자적인 HEM-플랫폼 기술을 활용하여 신약을 연구 및 개발하고 있습니다.